← Back to Search

Anti-tumor antibiotic

Tafasitamab + Lenalidomide + Rituximab for Follicular & Marginal Zone Lymphoma (InMIND Trial)

Phase 3
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
ECOG performance status of 0 to 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 years
Awards & highlights

InMIND Trial Summary

This trial is exploring whether adding tafasitamab to lenalidomide and rituximab improves treatment of patients with relapsed/refractory FL or MZL.

Who is the study for?
This trial is for adults with relapsed/refractory Follicular Lymphoma or Marginal Zone Lymphoma who've had prior anti-CD20 immunotherapy or chemo-immunotherapy. Participants must be able to take blood clot prevention meds, not be pregnant or breastfeeding, and have no major heart issues, active infections, HIV/HCV/HBV, CNS lymphoma involvement, or recent other lymphoma treatments.Check my eligibility
What is being tested?
The study tests if adding Tafasitamab to the combination of Lenalidomide and Rituximab improves outcomes for patients compared to a placebo plus Lenalidomide and Rituximab. It's a Phase 3 trial where participants are randomly assigned to either the drug group or placebo group without knowing which one they're in.See study design
What are the potential side effects?
Possible side effects include reactions at the infusion site, low blood counts leading to increased infection risk or bleeding problems, fatigue, rash, digestive issues like nausea and diarrhea. There may also be an increased risk of developing new cancers.

InMIND Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lymphoma is confirmed to be of a specific type and grade.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I have been treated with a therapy targeting CD20 before.
Select...
My cancer has returned or worsened after treatment.

InMIND Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS) in FL population
Secondary outcome measures
Best Overall Response Rate in FL and overall population
Complete Response in FL population
Complete Response in Overall population
+7 more

InMIND Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm A : tafasitamab + rituximab + lenalidomideExperimental Treatment3 Interventions
Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
Group II: Arm B : placebo+rituximab+lenalidomidePlacebo Group3 Interventions
Adult patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1 to 3a or R/R Marginal Zone Lymphoma (MZL)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
rituximab
2000
Completed Phase 3
~2760
lenalidomide
2012
Completed Phase 3
~3920

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
364 Previous Clinical Trials
54,511 Total Patients Enrolled

Media Library

Lenalidomide (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT04680052 — Phase 3
Marginal Zone Lymphoma Research Study Groups: Arm A : tafasitamab + rituximab + lenalidomide, Arm B : placebo+rituximab+lenalidomide
Marginal Zone Lymphoma Clinical Trial 2023: Lenalidomide Highlights & Side Effects. Trial Name: NCT04680052 — Phase 3
Lenalidomide (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04680052 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When did tafasitamab receive FDA clearance?

"Tafasitamab is considered safe, as it has been studied in multiple Phase 3 trials with positive efficacy data."

Answered by AI

What are the most common reasons that patients are prescribed tafasitamab?

"Tafasitamab is most often used as a treatment for diffuse large b-cell lymphoma (dlbcl). However, it can also be used to ameliorate other b-cell lymphomas and polyangiomas that have not responded well to at least two rounds of systemic chemotherapy."

Answered by AI

Does this research have a large presence in Canada?

"Right now, there are 50 enrolment sites for this study. They are situated in QU�BEC, Quã©bec, Halifax and other cities. If you want to take part in this trial, choose the enrolment site that is the most convenient for you to minimize travel."

Answered by AI

Are there any precedents for tafasitamab's usage in medical treatments?

"Tafasitamab was first studied in 1993 at the National Institutes of Health Clinical Center. As of now, there have been 3785 completed studies with 631 currently active studies. Many of these trials are taking place in QU�BEC and Nova Scotia."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0

How responsive is this trial?

Typically responds via
Phone Call
Recent research and studies
clinicaltrials.govStudy
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
2021. "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04680052.
All > Marginal Zone Lymphoma > Follicular Lymphoma
~163 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top